226
15. 3. 2005.
Bortezomib in recurrent and/or refractory multiple myeloma
Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date.